First person profile: Michelle M. Le Beau, PhD: Dr Le Beau's fascination with cancer cytogenetics has contributed to vast improvements in the treatment of certain cancers based on genetic subgroups.

Abstract

This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, the life‐long fascination with cancer cytogenetics of Michelle M. Le Beau, PhD, has contributed to vast improvements in the treatment of certain cancers based on genetic subgroups. In addition, two studies show benefits for patients with resectable non‐small cell lung cancer by adding perioperative durvalumab to chemotherapy and through using amivantamab in treatment‐naive patients and in patients who experience relapse.